I think it may be a lot less than that. If I'm no
Post# of 148115
If I'm not mistaken, someone here reported that the cost was $350 per does in the Philippines. 200k vials is 100k doses. 100k x $350 = $35,000,000.
This doesn't take into account Chiral's cut. I don't know what the normal split would be in the Philippines, anyone else here know the split for Vyera's take here in the US.
Still a lot of revenue for this small company. With a SP increase on actual sales and this revenue, NASDAQ uplist might be a lot closer.